Difference between revisions of "Part:BBa K2100017:Experience"

 
Line 5: Line 5:
  
 
===Applications of BBa_K2100017===
 
===Applications of BBa_K2100017===
We characterized the repressor TAL14 by creating a plasmid TRE:TAL14, containing TAL14 under the control of a doxycycline inducible promoter, TRE. This allowed for us to modulate the repressor expression by varying the concentrations of doxycycline added. We also created a repressible promoter controlling the expression of a fluorescent protein. This plasmid allowed for us to measure the repression occurring.
+
We characterized the repressor TAL21 by creating a plasmid TRE:TAL14, containing TAL21 under the control of a doxycycline inducible promoter, TRE. This allowed for us to modulate the repressor expression by varying the concentrations of doxycycline added. We also created a repressible promoter controlling the expression of a fluorescent protein. This plasmid allowed for us to measure the repression occurring.
  
  
 
https://static.igem.org/mediawiki/2016/a/ab/MIT_repressor_expt.png
 
https://static.igem.org/mediawiki/2016/a/ab/MIT_repressor_expt.png
  
In order for us to analyze the level of repression, we need to see sustained presence. Upon increasing the concentration of doxycycline, we were unable to see that sustained presence of the repressors. From the results of testing TAL14 below, it can be seen that although there is activation early on, the production of repressor falls at 500 nM. This could possible be due to errors in doxycycline dilutions at 500 nM and above.  
+
In order for us to analyze the level of repression, we need to see sustained presence. Upon increasing the concentration of doxycycline, we were unable to see that sustained presence of the repressors. From the results of testing TAL21 below, it can be seen that although there is activation early on, the production of repressor falls at 500 nM. This could possible be due to errors in doxycycline dilutions at 500 nM and above.  
  
 
[image here]
 
[image here]

Latest revision as of 15:36, 19 October 2016


This experience page is provided so that any user may enter their experience using this part.
Please enter how you used this part and how it worked out.

Applications of BBa_K2100017

We characterized the repressor TAL21 by creating a plasmid TRE:TAL14, containing TAL21 under the control of a doxycycline inducible promoter, TRE. This allowed for us to modulate the repressor expression by varying the concentrations of doxycycline added. We also created a repressible promoter controlling the expression of a fluorescent protein. This plasmid allowed for us to measure the repression occurring.


MIT_repressor_expt.png

In order for us to analyze the level of repression, we need to see sustained presence. Upon increasing the concentration of doxycycline, we were unable to see that sustained presence of the repressors. From the results of testing TAL21 below, it can be seen that although there is activation early on, the production of repressor falls at 500 nM. This could possible be due to errors in doxycycline dilutions at 500 nM and above.

[image here]

User Reviews

UNIQ912ef3ffb42b2a55-partinfo-00000000-QINU UNIQ912ef3ffb42b2a55-partinfo-00000001-QINU